{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:34:34Z","timestamp":1770503674571,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T00:00:00Z","timestamp":1219968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> von Willebrand disease (VWD) is a heterogeneous bleeding disorder with symptoms in affected patients ranging from mild effects to potentially devastating haemorrhagic events. Desmopressin (DDAVP) and von Willebrand factor\/factor VIII (VWF\/FVIII) concentrates are the principal treatments. Haemate<jats:sup>\u00ae<\/jats:sup> P\/Humate\u2010P<jats:sup>\u00ae<\/jats:sup> is an intermediate\u2010purity VWF\/FVIII concentrate with extensive clinical experience in VWD. This concentrate has been shown to correct haemostatic defects of VWD, with efficacy ratings of good\/excellent in nearly all patients treated for bleeding or surgical events. Haemate P\/Humate\u2010P has a high content of the high molecular weight (HMW) VWF multimer fraction, which has been shown to be very effective in achieving haemostasis. The HMW VWF multimer pattern in Haemate P\/Humate\u2010P is more similar to that of normal human plasma (94% for Haemate P\/Humate\u2010P vs. 100% for normal human plasma) than that of other VWF\/FVIII concentrates and correlates with functional VWF activities including ristocetin cofactor activity (VWF:RCo) and collagen\u2010binding activity. The recommended dosing of Haemate P\/Humate\u2010P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P\/Humate\u2010P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. While DDAVP is effective in a large proportion of VWD patients, it may not provide adequate haemostasis in all situations. In such cases, Haemate P\/Humate\u2010P is an effective replacement concentrate for all types of VWD in both adult and paediatric patients.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01850.x","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T07:56:39Z","timestamp":1219996599000},"page":"39-46","source":"Crossref","is-referenced-by-count":31,"title":["Haemate<sup>\u00ae<\/sup> P\/Humate\u2010P<sup>\u00ae<\/sup> for the treatment of von Willebrand disease: considerations for use and clinical experience"],"prefix":"10.1111","volume":"14","author":[{"given":"G.","family":"AUERSWALD","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"KREUZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"94","article-title":"Von Willebrand disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80384-1"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10327"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00622.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00886.x"},{"key":"e_1_2_7_8_2","volume-title":"Humate\u2010P\u00ae antihemophilic factor\/von Willebrand factor complex (human): prescribing information","author":"CSL Behring GmbH"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200406000-00006"},{"issue":"1","key":"e_1_2_7_10_2","article-title":"Determination of high molecular weight von Willebrand factor multimers and their impact on specific VWF activities in VWF\/FVIII\u2010concentrates","volume":"1","author":"Walter O","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_7_11_2","article-title":"Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF\u2010collagen\u2010binding assays in VWF\/FVIII\u2010concentrates","volume":"1","author":"Suiter T","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050184"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0133"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949668"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb02031.x"},{"key":"e_1_2_7_18_2","first-page":"298","article-title":"Experience with Haemate P in von Willebrand\u2019s disease in adults","volume":"24","author":"Scharrer I","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320748"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30490273452.x"},{"key":"e_1_2_7_21_2","first-page":"304","article-title":"Haemate P in children with von Willebrand\u2019s disease","volume":"24","author":"Kreuz W","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_7_22_2","first-page":"289","article-title":"Plasma product treatment in various types of von Willebrand\u2019s disease","volume":"24","author":"Berntorp E","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161505"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319766"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_7_27_2","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand factor concentrate (Haemate\u2010P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand\u2019s disease","volume":"88","author":"Franchini M","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0037-1614448","article-title":"Safety and efficacy of continuous infusion of a combined factor VIII\u2013von Willebrand factor (vWF) concentrate (Haemate\u2010P) in patients with von Willebrand disease","volume":"81","author":"Lubetsky A","year":"1999","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_2_7_32_2","article-title":"The use of two plasma derived factor VIII concentrates in type 2A von Willebrand\u2019s disease (VWD)","volume":"1","author":"Morley N","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_33_2","first-page":"107","article-title":"Factor VIII concentrate: hepatitis\u2010safe preparation, virus inactivation and clinical experience","author":"Heimburger N","year":"1984","journal-title":"Proc 4th Inter Symp Hemophilia Treatment"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910263211702"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92420-1"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-27820"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01850.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01850.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:36:08Z","timestamp":1694612168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01850.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,29]]},"references-count":35,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01850.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01850.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,29]]}}}